Research Groups

Biotechnology Development

Group Leader

Research Interests and Description
Group Members

Sergio G. Tisminetzky

International Centre for Genetic Engineering and Biotechnology
Padriciano 99
34012 Trieste, Italy

E-mail: sergio@icgeb.org
Office tel: +39-040-3757315
Lab tel: +39-040-3757368
Office fax: +39-040-226555

Education

Buenos Aires University, Faculty of Pharmacia and Biochemistry, Buenos Aires, Argentina, BSc 1975
Buenos Aires University, Faculty of Pharmacia and Biochemistry, Buenos Aires, Argentina, PhD, 1987

Career History

Since 1999, Group Leader of Biotech Development, ICGEB, Trieste, Italy
1990-1998, Research Scientist, Molecular Pathology Group, ICGEB, Trieste, Italy.
1987-1990, Research Fellow, Istituto Sieroterapico Milanese, Milan, Italy.
1980-1987, Research Fellow, National Research Council of Buenos Aires, Argentina.
1975-1980, Research Fellow, Children's Hospital of Buenos Aires, Argentina.

Teaching Activity

Teaching and tutoring at the National Research Council of Buenos Aires, Argentina and at the Department of Biology, University of Buenos Aires, Argentina (1984-1986).

Scientific Activity

Focus on the development of virus recombinmant vaccines (scafolding protein-antigen presentation) and diagnostics of bacterial vaccines and viral disease (HIV-1 and HCV genotypes).
Since 1996 focus on the development of simple and innovative technologies for the production of recombinant pharmaceuticals. Developing recombinant strains (E. coli, CHO cells and Pichia pastoris), downstream technologies and quality control procedures for the production of : erythropoietin (EPO), interferon alpha 2 (IFN alpha 2A/B), granulocyte colony stimulating factor (G-CSF) and human recombinant Insulin.
39 full papers published in peer-reviewed international journals

Selected Publications

Zago, P., Baralle, M., Ayala, Y.M., Skoko, N., Zacchigna, S., Buratti, E., Tisminetzky, S. 2009. Improving human interferon-beta production in mammalian cell lines by insertion of an intronic sequence within its naturally uninterrupted gene. Biotechnol. Appl. Biochem. 52, 191-198

Senerovic, L., Stankovic, N., Spizzo, P., Basso, A., Gardossi, L., Vasiljevic, B., Ljubijankic, G., Tisminetzky, S., Degrassi, G. 2006. High-level production and covalent immobilisation of Providencia rettgeri penicillin G acylase (PAC) from recombinant Pichia pastoris for the development of a novel and stable biocatalyst of industrial applicability. Biotechnol. Bioeng. 93, 344-354c

Buratti, E., Brindisi, A., Giombi, M., Tisminetzky, S., Ayala, Y.M., Baralle, F.E. 2005. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 280, 37572-37584

Vandelli, C., Renzo, F., Romano, l., Tisminetzky, S., De Palma, M., Stroffolini, T., Ventura, E., Zanetti, A. 2004. Lack of evidence of sexual transmission of hepatites C among monogamous couples: results of a ten-year prospective follow-up study. Am. J. Gastroenterol. 99, 855-859

Fló, J., Tisminetzky, S., Baralle, F.E. 2001. Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine 19, 1772-1782